This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
BQ-123
DrugBank Accession Number
DB12054
Background

BQ-123 has been investigated for the basic science and treatment of Coronary Artery Disease, Aorto-coronary Bypass Grafting, and ST-Elevation Myocardial Infarction.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 610.712
Monoisotopic: 610.311497716
Chemical Formula
C31H42N6O7
Synonyms
Not Available
External IDs
  • BQ123

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololAcebutolol may increase the hypotensive activities of BQ-123.
AceclofenacThe therapeutic efficacy of BQ-123 can be decreased when used in combination with Aceclofenac.
AcemetacinThe therapeutic efficacy of BQ-123 can be decreased when used in combination with Acemetacin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of BQ-123.
AlclofenacThe therapeutic efficacy of BQ-123 can be decreased when used in combination with Alclofenac.
AldesleukinAldesleukin may increase the hypotensive activities of BQ-123.
AlfentanilAlfentanil may decrease the antihypertensive activities of BQ-123.
AlfuzosinAlfuzosin may increase the hypotensive activities of BQ-123.
AliskirenAliskiren may increase the hypotensive activities of BQ-123.
AlmotriptanAlmotriptan may decrease the antihypertensive activities of BQ-123.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Bq 123 Sodium05427HSQ1I136655-57-7FLIKEIGEOXCRRG-JKNHBXRPSA-M

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Oligopeptides
Alternative Parents
Cyclic peptides / Macrolactams / 3-alkylindoles / Alpha amino acids and derivatives / Substituted pyrroles / Benzenoids / Tertiary carboxylic acid amides / Pyrrolidines / Heteroaromatic compounds / Secondary carboxylic acid amides
show 9 more
Substituents
3-alkylindole / Alpha-amino acid or derivatives / Alpha-oligopeptide / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid / Cyclic alpha peptide
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
cyclic peptide (CHEBI:2965)
Affected organisms
Not Available

Chemical Identifiers

UNII
S2A8YZM151
CAS number
136553-81-6
InChI Key
VYCMAAOURFJIHD-PJNXIOHISA-N
InChI
InChI=1S/C31H42N6O7/c1-16(2)12-21-27(40)33-22(13-18-15-32-20-9-6-5-8-19(18)20)28(41)35-23(14-25(38)39)31(44)37-11-7-10-24(37)29(42)36-26(17(3)4)30(43)34-21/h5-6,8-9,15-17,21-24,26,32H,7,10-14H2,1-4H3,(H,33,40)(H,34,43)(H,35,41)(H,36,42)(H,38,39)/t21-,22+,23+,24-,26+/m0/s1
IUPAC Name
2-[(3R,6S,9R,12R,17aS)-9-[(1H-indol-3-yl)methyl]-6-(2-methylpropyl)-1,4,7,10,13-pentaoxo-3-(propan-2-yl)-hexadecahydro-1H-pyrrolo[1,2-a]1,4,7,10,13-pentaazacyclopentadecan-12-yl]acetic acid
SMILES
CC(C)C[C@@H]1NC(=O)[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC(O)=O)NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC1=O)C(C)C

References

General References
Not Available
KEGG Compound
C11587
PubChem Compound
443289
PubChem Substance
347828364
ChemSpider
391535
BindingDB
50197954
ChEBI
2965
ChEMBL
CHEMBL314691
ZINC
ZINC000003926620
Wikipedia
BQ-123

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentPulmonary Hypertension (PH)1
2CompletedTreatmentReperfusion Injury, Myocardial1
2CompletedTreatmentST Segment Elevation Myocardial Infarction (STEMI)1
2Unknown StatusTreatmentAorto-coronary Bypass Grafting / Coronary Artery Disease (CAD)1
1CompletedBasic ScienceChronic Kidney Disease (CKD) / Proteinuria1
1CompletedDiagnosticCoronary Vessels / Endothelins / Vascular Resistance1
1RecruitingBasic ScienceCardiovascular Disease (CVD) / Cardiovascular Risk / Vasoconstriction1
1RecruitingBasic ScienceChronic Obstructive Pulmonary Disease (COPD) / Heart Failure / High Blood Pressure (Hypertension) / Pulmonary Arterial Hypertension (PAH)1
1WithdrawnOtherHigh Blood Pressure (Hypertension) / Multiple System Atrophy (MSA) / Progressive autonomic failure1
0CompletedBasic ScienceHeart Failure1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.13 mg/mLALOGPS
logP1.09ALOGPS
logP0.84ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)4.04ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area189.8 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity158.59 m3·mol-1ChemAxon
Polarizability62.8 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 21:16 / Updated at June 12, 2020 16:53